Applied Therapeutics, Inc.

NasdaqGM:APLT Stock Report

Market Cap: US$626.9m

Applied Therapeutics Balance Sheet Health

Financial Health criteria checks 2/6

Applied Therapeutics tiene unos fondos propios totales de $-11.0M y una deuda total de $775.0K, lo que sitúa su ratio deuda/fondos propios en -7%. Sus activos y pasivos totales son $45.2M y $56.2M respectivamente.

Key information

-1.8%

Debt to equity ratio

US$310.00k

Debt

Interest coverage ration/a
CashUS$49.90m
Equity-US$17.15m
Total liabilitiesUS$71.98m
Total assetsUS$54.83m

Recent financial health updates

Recent updates

Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible

Feb 16

Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

Feb 16
Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

Nov 13
Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Aug 11
We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

May 19
We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock

Jan 19

Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

Nov 11
Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Aug 13
Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Applied Therapeutics trades higher on FDA Fast Track designation for rare metabolic disorder

Jun 17

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

May 15
Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)

Feb 26
Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)

How Much Of Applied Therapeutics, Inc. (NASDAQ:APLT) Do Insiders Own?

Feb 18
How Much Of Applied Therapeutics, Inc. (NASDAQ:APLT) Do Insiders Own?

Applied Therapeutics to resume galactosemia study for AT-007

Feb 02

Applied Therapeutics, Inc. (NASDAQ:APLT) Insiders Have Been Selling

Nov 24
Applied Therapeutics, Inc. (NASDAQ:APLT) Insiders Have Been Selling

Applied Therapeutics EPS misses by $0.21

Nov 12

Financial Position Analysis

Pasivos a corto plazo: APLT tiene fondos propios negativos, que es una situación más grave que activos a corto plazo que no cubren pasivos a corto plazo.

Pasivo a largo plazo: APLT tiene fondos propios negativos, lo que es una situación más grave que el hecho de que los activos a corto plazo no cubran los pasivos a largo plazo.


Debt to Equity History and Analysis

Nivel de deuda: APLT tiene fondos propios negativos, que es una situación más grave que un alto nivel de endeudamiento.

Reducción de la deuda: APLT's tiene fondos propios negativos, por lo que no necesitamos comprobar si su deuda se ha reducido con el tiempo.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Cash runway estable: APLT tiene suficiente cash runway para 8 meses según el último flujo de caja libre declarado [flujo de caja libre]], pero desde entonces ha obtenido capital adicional.

Pronóstico de cash runway: APLT se prevé que disponga de suficiente liquidez para 7 meses según las estimaciones de flujo de caja libre, pero desde entonces ha obtenido capital adicional.


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.